Aquatic Capital Management LLC Sage Therapeutics, Inc. Transaction History

Aquatic Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $119,168 - $172,480	-6,400 Reduced 35.75%	11,500 $215,000
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $167,580 - $218,148	9,800 Added 120.99%	17,900 $388,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $41,875 - $122,449	2,500 Added 44.64%	8,100 $167,000
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $227,640 - $333,424	5,600 New	5,600 $263,000
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $142,032 - $190,388	-4,400 Reduced 40.74%	6,400 $251,000
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $297,216 - $410,292	10,800 New	10,800 $349,000
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $61,420 - $91,420	-2,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $74,120 - $94,220	2,000 New	2,000 $85,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aquatic Capital Management LLC with notifications on news.